Compounded Mounjaro Vermont — What You Need to Know

What Compounded Mounjaro Actually Is

Mounjaro (tirzepatide) is an FDA-approved prescription medication manufactured by Eli Lilly for type 2 diabetes and weight management. Compounded Mounjaro is not manufactured by Eli Lilly. Instead, compounding pharmacies create versions of tirzepatide under the Food, Drug, and Cosmetic Act's section 503A or 503B frameworks, which permit pharmacies to prepare patient-specific formulations when certain conditions are met.

The distinction matters for immigration applicants preparing for USCIS medical examinations. Panel physicians — the civil surgeons authorized to conduct Immigration and Nationality Act (INA) medical exams — document all current medications on Form I-693. The medication list becomes part of the permanent immigration file. Compounded medications occupy a regulatory category distinct from FDA-approved commercial drugs, and that distinction can raise questions during the review process.

Vermont permits compounding pharmacies to operate under state Board of Pharmacy oversight. As of January 2026, Vermont law requires compounding facilities to register with the state and comply with USP standards for sterile and non-sterile compounding. The state does not prohibit compounded GLP-1 receptor agonists like tirzepatide, but federal FDA enforcement actions in 2024 and 2025 targeted specific compounding practices nationwide, including claims that some compounders marketed tirzepatide formulations while the branded drug remained on the FDA shortage list.

Why Immigration Applicants Encounter This Issue

Immigration medical exams under INA Section 212(a)(1) require applicants to disclose all prescription medications to the panel physician. The exam determines medical admissibility — whether the applicant has a communicable disease of public health significance, lacks required vaccinations, has a physical or mental disorder with associated harmful behavior, or is a drug abuser or addict.

Medications themselves rarely affect admissibility findings. What affects admissibility is the underlying condition the medication treats, whether that condition is documented and controlled, and whether the prescribing pattern suggests misuse. Compounded medications raise documentation questions because:

1. The prescribing physician must justify why a compounded formulation was chosen over the FDA-approved commercial product.
2. Panel physicians may request proof that the compounding pharmacy operates lawfully under state and federal frameworks.
3. USCIS adjudicators reviewing the I-693 may issue a Request for Evidence (RFE) if the medication list contains items that appear outside standard therapeutic channels.

These are procedural scrutiny points, not automatic disqualifiers. The applicant who can produce a prescription from a licensed Vermont provider, pharmacy documentation showing lawful compounding under Vermont Board of Pharmacy registration, and medical records explaining the therapeutic rationale clears the documentation threshold. The applicant using a compounded medication purchased without a prescription, or from an out-of-state online vendor operating in a regulatory gray zone, faces a harder documentation path.

The FDA's Position on Compounded Tirzepatide

The FDA permits compounding pharmacies to prepare versions of FDA-approved drugs only when certain conditions are met. Under 21 U.S.C. § 353a (section 503A), a compounding pharmacy may prepare a compounded drug if:

• It is compounded for an identified individual patient based on a valid prescription.
• The drug is not a copy of a commercially available product unless that product is on the FDA drug shortage list.
• The compounder does not compound regularly or in inordinate amounts any drug on the FDA's list of drugs that present demonstrable difficulties for compounding.

Mounjaro was placed on the FDA drug shortage list in late 2022. The shortage designation permitted compounding pharmacies to prepare tirzepatide formulations legally during the shortage period. In October 2024, the FDA removed Mounjaro from the shortage list, then reinstated it briefly in December 2024 following litigation, and removed it again in early 2025. As of January 2026, tirzepatide is not on the FDA shortage list, meaning compounding pharmacies may no longer lawfully compound it under the 503A framework unless another statutory exemption applies.

Enforcement follows the shortage list in real time. Immigration applicants using compounded tirzepatide must verify the current FDA shortage list status before their medical exam, because the legality of their medication source depends on it. The FDA publishes the current shortage list at accessdata.fda.gov/scripts/drugshortages.

Vermont-Specific Compounding Rules

Vermont law governs pharmacy compounding through Title 26, Chapter 36 of the Vermont Statutes and Vermont Board of Pharmacy regulations. Vermont compounding pharmacies must:

• Register with the Vermont Board of Pharmacy and renew registration biennially.
• Comply with United States Pharmacopeia (USP) Chapters 795 (non-sterile compounding) and 797 (sterile compounding).
• Maintain records of all compounded preparations for at least two years.
• Source active pharmaceutical ingredients (APIs) from FDA-registered suppliers.

Vermont does not operate a separate state-level approval process for compounded GLP-1 medications. The state defers to federal FDA frameworks for what may be compounded. If the FDA shortage list does not include tirzepatide, a Vermont pharmacy compounding it operates outside the 503A exemption and must qualify under 503B (outsourcing facility) registration, which carries additional federal oversight requirements.

Applicants obtaining compounded Mounjaro in Vermont should request written documentation from the pharmacy confirming:

1. The pharmacy's Vermont Board of Pharmacy registration number and status.
2. Whether the pharmacy operates under 503A or 503B federal registration.
3. The source of the tirzepatide API and its FDA registration status.
4. The date the prescription was filled and whether tirzepatide was on the FDA shortage list on that date.

This documentation supports the I-693 medication disclosure if the panel physician or USCIS requests clarification.

What Panel Physicians Look For on Form I-693

Panel physicians complete Form I-693 (Report of Medical Examination and Vaccination Record) for all applicants adjusting status in the United States or applying for an immigrant visa abroad. The form requires the applicant to list all current prescription medications by name, dosage, and prescribing physician.

The physician does not adjudicate medication legality — that is not within the scope of the I-693. The physician documents what the applicant reports and evaluates whether the underlying medical condition affects admissibility. For diabetes or weight-management medications like tirzepatide, the condition itself does not trigger inadmissibility unless it is associated with harmful behavior, which diabetes and obesity are not.

What prompts scrutiny:

• Medications listed without a corresponding diagnosis in the medical history section.
• Medications obtained from sources the applicant cannot document with a prescription.
• Controlled substances (tirzepatide is not a controlled substance, so this does not apply here).
• Medications on the applicant's list that do not match the prescribing pattern in the medical records the applicant provides.

The panel physician may ask the applicant to provide the prescription and pharmacy documentation for any medication that appears outside standard channels. Applicants using compounded Mounjaro should bring the prescription, the pharmacy's information, and a letter from the prescribing physician explaining the therapeutic rationale.

Here's the Honest Answer: Compounding Exists in a Gray Zone Immigration Doesn't Handle Well

Let's be direct: immigration medical exams are designed around straightforward clinical documentation. The applicant takes an FDA-approved medication prescribed by a licensed physician for a diagnosed condition, and the panel physician documents it. That pattern clears review without delay.

Compounded medications disrupt that pattern not because they are inherently problematic, but because they require the applicant to explain why the compounded version was necessary, whether the compounding was lawful, and whether the sourcing meets federal standards. USCIS adjudicators are not pharmacists. When they see a compounded medication on an I-693, they often issue an RFE asking for documentation the applicant may not have thought to obtain.

The RFE does not deny the case, but it delays it. Responding to an RFE costs time — typically 60 to 90 days from issuance to final adjudication after the response is filed — and attorney fees if the applicant hires counsel to draft the response. The applicant who anticipated the documentation need and brought the pharmacy's registration proof, the prescribing rationale, and the FDA shortage list status to the medical exam avoids the RFE entirely.

There is no immigration regulation that bars compounded medications. What exists is a documentation standard, and compounded medications require more documentation to meet it.

Comparison: Compounded vs. Commercial Mounjaro for Immigration Purposes

What If You're Already Using Compounded Mounjaro and Have an I-693 Coming Up?

Bring documentation to the exam. Specifically:

1. The prescription from your Vermont provider, showing the prescribing physician's name, license number, the medication name (tirzepatide), dosage, and fill date.
2. Pharmacy documentation: the label from the compounded medication, the pharmacy's name and address, and if possible a letter from the pharmacy confirming its Vermont Board of Pharmacy registration and the source of the tirzepatide API.
3. A letter from your prescribing physician explaining why the compounded version was prescribed instead of commercial Mounjaro — cost, dosage customization, shortage-period prescription that you continued, or another clinical reason.
4. Your own check of the FDA drug shortage list the week before your exam, printed from accessdata.fda.gov, showing whether tirzepatide was on the list at the time your prescription was filled.

The panel physician includes the medication on the I-693 as reported. If the physician requests supporting documents, you provide them at the exam. If the physician does not request them, keep the documentation in your file — if USCIS issues an RFE later, you respond with the same materials.

What If USCIS Issues an RFE About Your Compounded Medication?

RFEs on I-693 medication disclosures typically request:

• Proof that the medication was lawfully prescribed.
• Documentation that the source pharmacy operates under applicable state and federal law.
• Clarification of the medical condition being treated and whether it affects admissibility.

The response assembles the documentation listed above and pairs it with a cover letter explaining:

• The prescription was issued by a Vermont-licensed physician for a diagnosed medical condition (type 2 diabetes or weight management).
• The compounding pharmacy holds a current Vermont Board of Pharmacy registration and complied with federal compounding frameworks in effect at the time of dispensing.
• The underlying condition does not render the applicant inadmissible under INA 212(a)(1), as diabetes and obesity are not communicable diseases, do not require vaccinations, and are not physical or mental disorders with associated harmful behavior.

The RFE response deadline is the date stated in the RFE notice — typically 87 days from the date the notice was mailed. Late responses are treated as abandoned applications. If you cannot assemble the pharmacy documentation within the deadline, contact the pharmacy immediately and explain that the documentation is required for a federal immigration filing. Most pharmacies understand the urgency and can produce a compliance letter within one to two weeks.

What If the Compounding Pharmacy You Used Is No Longer Operating?

Vermont Board of Pharmacy records are public. If the pharmacy that compounded your medication has closed or had its license suspended, you can verify its status at the time your prescription was filled by requesting records from the Board. Contact the Vermont Office of Professional Regulation, Board of Pharmacy, at 802-828-1505 or through their online portal at sos.vermont.gov/opr.

The Board maintains registration records showing the dates a pharmacy was licensed. If the pharmacy was registered at the time it filled your prescription, that fact establishes lawful sourcing even if the pharmacy later closed. Include the Board's confirmation letter in your RFE response.

If the pharmacy was never registered, or if it operated outside the dates of its registration when it filled your prescription, the compounded medication was sourced unlawfully. That does not make you inadmissible, but it complicates the I-693. Consult an immigration attorney before responding to the RFE. The solution may involve obtaining a new prescription for commercial Mounjaro, discontinuing the compounded version, and having the panel physician amend the I-693 to reflect the current medication list. Amended I-693s are permitted under USCIS policy, but the amendment must be completed before the underlying application is adjudicated.

The Statutory Framework for Immigration Medical Exams

Form I-693 implements INA Section 212(a)(1)(A), which renders inadmissible any applicant who:

• Has a communicable disease of public health significance (as defined by Executive Order and CDC regulation).
• Fails to present documentation of required vaccinations.
• Has a physical or mental disorder and behavior associated with the disorder that may pose, or has posed, a threat to the property, safety, or welfare of the applicant or others.
• Is determined to be a drug abuser or addict.

The medication list on the I-693 informs the panel physician's evaluation of these categories. A medication alone does not trigger inadmissibility. The condition the medication treats, and the applicant's behavior related to that condition, are what the statute evaluates.

Diabetes, treated with tirzepatide or any other medication, does not fall under any of the four inadmissibility categories. Weight management similarly does not. The medication disclosure exists to give the panel physician a complete clinical picture, not to penalize the applicant for taking a prescribed medication.

What does affect admissibility: if the applicant obtained the medication without a prescription, or if the medication is a controlled substance obtained unlawfully, the procurement pattern may suggest drug abuse under INA 212(a)(1)(A)(iv). Tirzepatide is not a controlled substance under the Controlled Substances Act, so this provision does not apply here even if the sourcing was irregular. The sourcing question is a documentation question for the I-693, not a statutory inadmissibility finding.

Cost and Access Considerations

Compounded tirzepatide typically costs less than branded Mounjaro because compounding pharmacies are not bound by the manufacturer's pricing structure. As of early 2026, commercial Mounjaro costs approximately $1,000 to $1,200 per month without insurance. Compounded versions range from $200 to $500 per month depending on the pharmacy and dosage.

Insurance coverage differs. Most commercial health plans cover FDA-approved Mounjaro for type 2 diabetes when prescribed by an in-network provider. Coverage for weight management is less consistent. Compounded tirzepatide is rarely covered by insurance, even when the underlying condition is covered, because insurers do not recognize compounded versions as equivalent to the FDA-approved product.

For immigration applicants, cost is a secondary consideration to documentation. Saving $600 per month on medication costs creates no immigration benefit if the compounded version delays your I-693 review by three months or triggers an RFE that costs $1,500 in attorney fees to resolve. Evaluate the sourcing decision with the documentation burden in mind, not only the price difference.

Why This Topic Intersects With Immigration Law

This content exists because immigration applicants in Vermont — and nationwide — are using compounded GLP-1 medications in increasing numbers, and the intersection between compounding regulation and immigration medical exam documentation is poorly understood. Panel physicians encounter compounded medications on I-693s without clear guidance on how to document them. USCIS adjudicators see them on I-693s without clear standards for when to request additional evidence.

The Law Offices of Peter D. Chu represents clients across the full range of visa categories, adjustment of status cases, and naturalization applications. The firm does not provide medical advice or evaluate compounding pharmacy compliance — that is outside the scope of immigration law practice. What the firm does is prepare clients for the I-693 process, flag documentation gaps before they become RFEs, and respond to RFEs when medication sourcing questions arise.

If you are preparing for an immigration medical exam and your current medication list includes a compounded drug, the documentation you bring to the exam determines whether the exam proceeds smoothly or triggers a delay. The exam itself is not the place to discover you lack the records the panel physician needs.

This article is for general informational purposes only and does not constitute legal or medical advice. Immigration outcomes depend on individual facts, and no article can predict the result of a specific case. Reading this content does not create an attorney-client relationship with the Law Offices of Peter D. Chu. Consult a licensed immigration attorney for advice tailored to your situation. Medical questions about compounded medications, prescribing decisions, and pharmacy sourcing should be directed to a licensed healthcare provider or pharmacist.

For a comprehensive review of your immigration case, including I-693 preparation and RFE response strategy, schedule a consultation with the Law Offices of Peter D. Chu. The consultation fee is $250. Contact the firm at 4615 Convoy St, San Diego, CA 92111, or call 858-268-8823. Office hours are Monday through Friday, 8:30 AM to 5:30 PM.

Schedule a consultation with the Law Offices of Peter D. Chu — 4615 Convoy St, San Diego, CA 92111 · 858-268-8823 · Mon–Fri, 8:30 AM–5:30 PM. Consultation fee: $250.